|
|||||||||||||||||||||||||||||||||||||
Decision XVII/14: Difficulties faced by some Parties operating under paragraph 1 of Article 5 of the Montreal Protocol with respect to chlorofluorocarbons used in the manufacture of metered-dose inhalers
The Seventeenth Meeting of the Parties decided in Dec. XVII/14: Acknowledging that Parties not operating under paragraph 1 of Article 5 of the Montreal Protocol have phased out chlorofluorocarbons but under specific conditions, can apply for essential-use exemption for the consumption of chlorofluorocarbons in the manufacture of metered-dose inhalers as specified by the Meeting of the Parties, Concerned that Parties operating under paragraph 1 of Article 5 of the Protocol which consume chlorofluorocarbons for the manufacture of metered-dose inhalers may find it difficult to phase out these substances without incurring economic losses to their countries, Calling upon the parent pharmaceutical companies to accelerate the transfer of non-chlorofluorocarbon technologies to their joint venture partners in developing countries, Noting the need for further work to be undertaken to assemble and document the new non-ozone-depleting substances methods of technology for metered-dose inhalers that would allow elimination of further uses of chlorofluorocarbons, Noting with concern that there is a serious risk that, for some Parties operating under paragraph 1 of Article 5, consumption levels in 2007 of chlorofluorocarbons for metered-dose inhaler uses may exceed the allowable amounts, Aware of the critical need by Parties operating under paragraph 1 of Article 5 for the consumption of metered-dose inhalers for protecting human health, Recognizing also the difficulties that may be faced by Parties operating under paragraph 1 of Article 5 in obtaining sufficient supply of Annex A, group I (chlorofluorocarbons) controlled substances during the period 2007-2009,
|
|||||||||||||||||||||||||||||||||||||
| © Ozone Secretariat 2004 | |||||||||||||||||||||||||||||||||||||